Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 clinical trial evaluating ERAS-0015 in combination with vopimetostat in patients with MTAPdel pancreatic or MTAPdel RASm non-small cell lung cancer (NSCLC).

Next Previous
Trial Profile

A Phase 1/2 clinical trial evaluating ERAS-0015 in combination with vopimetostat in patients with MTAPdel pancreatic or MTAPdel RASm non-small cell lung cancer (NSCLC).

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ERAS 0015 (Primary) ; Vopimetostat (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Tango Therapeutics

Most Recent Events

  • 16 Mar 2026 New trial record
  • 05 Mar 2026 According to Erasca media release, announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics to evaluate ERAS-0015 with vopimetostat. This agreement will support a Phase 1/2 clinical trial evaluating ERAS-0015 in combination with vopimetostat in patients with MTAPdel pancreatic or MTAPdel RASm non-small cell lung cancer (NSCLC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top